Onco Wiki - Drogas

Etoposide

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDDRUG-ETOPOSIDE
TipoFármaco
Aliaces
EtopofosEtoposide phosphate (Etopophos)En el toposarVP-16El sistema de control de la calidad de la sustancia activa se utiliza para determinar si la sustancia en cuestión es la sustancia que se utiliza en el ensayo.VepesídeoЕтопозид
Situaciónreviewed 2026-04-26 | pending_clinical_signoff
EnfermedadesDIS-ADRENOCORTICAL-CARCINOMA DIS-AITL DIS-AML DIS-ATLL DIS-BURKITT DIS-EATL DIS-HGBL-DH DIS-HSTCL DIS-NK-T-NASAL DIS-PMBCL DIS-PTCL-NOS DIS-SCLC DIS-TESTICULAR-GCT
FuentesSRC-NCCN-BCELL-2025

Datos sobre drogas

Claseantineoplásico — inhibidor de la topoisomerasa II (epipodofilotoxina)
MecanismoSemi-synthetic podophyllotoxin derivative; stabilizes the cleavable topoisomerase II–DNA complex, preventing strand religation and producing protein-linked DNA double-strand breaks that trigger apoptosis. Cell-cycle S/G2 phase active. Etoposide phosphate (Etopophos) is a water-soluble prodrug rapidly converted to etoposide by serum phosphatases, allowing faster IV administration without solvent reactions.
Dosificación típicaDA-EPOCH-R (DLBCL / Burkitt / HGBL): 50 mg/m²/day continuous IV days 1-4 (96-h infusion), starting dose; dose-adjusted up by ~20% per cycle if ANC nadir >0.5. BEACOPP escalated (Hodgkin): 200 mg/m² IV days 1-3. ICE (R/R DLBCL pre-ASCT): 100 mg/m² IV days 1-3. ESHAP: 40 mg/m²/day continuous IV days 1-4 (96-h infusion). AML 7+3 alternative / induction reinforcement: 100-150 mg/m² IV days 1-5. HLH-94/2004: 150 mg/m² IV twice weekly × 2 weeks then weekly. BEP (testicular): 100 mg/m² IV days 1-5 every 21 days × 3-4 cycles.
Ucrania registradaCierto
NSZU reembolsadoCierto
Ucrania verificada por última vez2026-04-27

Advertencias

Notas

Used widely in heme: DA-EPOCH-R (DLBCL / Burkitt / HGBL / PMBL), BEACOPP-escalated (Hodgkin), ICE / RICE (R/R DLBCL salvage), ESHAP (R/R lymphoma salvage), HLH-94/2004 (hemophagocytic lymphohistiocytosis), AML salvage / induction-intensification protocols, and BEP (germ-cell). Therapy-related AML with 11q23 (KMT2A/MLL fusion) is the principal late toxicity, more frequent with weekly than 3-weekly dosing (cumulative exposure threshold ~2 g/m²). Slow infusion (≥30-60 min) to avoid hypotension and infusion reactions; Etopophos phosphate prodrug allows faster infusion without solvent toxicity. Oral bioavailability variable (~50%) — IV preferred for curative protocols.

Utilizado por

Esquema terapéutico